---
title: "Pyxis Oncology Holds Special Stockholder Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305505274.md"
description: "Pyxis Oncology shareholders approved increasing authorized common stock from 190 million to 380 million shares at a special meeting on November 13, 2026. The charter amendment took effect upon filing. No adjournment was necessary as sufficient support was received for the share increase."
datetime: "2026-11-13T21:18:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305505274.md)
  - [en](https://longbridge.com/en/news/305505274.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305505274.md)
generator: "portal-rs"
---

# Pyxis Oncology Holds Special Stockholder Meeting

-   Pyxis Oncology shareholders approved increasing authorized common stock from 190,000,000 to 380,000,000 shares at the November 13, 2026, special meeting. \* The charter amendment took effect upon filing on November 13, 2026. \* Shareholders also authorized adjournments to solicit additional proxies if needed, but no adjournment was necessary because the share increase received sufficient support. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-460698), on November 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md)

## Related News & Research

- [PYXS: MICVO showed durable responses in phase 1, supporting a planned global Phase 3 trial](https://longbridge.com/en/news/306107284.md)
- [William Blair upgrades Pyxis Oncology to Outperform from Market Perform](https://longbridge.com/en/news/306274949.md)
- [Guggenheim Remains a Buy on Pyxis Oncology (PYXS)](https://longbridge.com/en/news/306281515.md)
- [Pyxis Oncology Presents MICVO Data Showing 36% Confirmed Response Rate in Advanced Head and Neck Cancer](https://longbridge.com/en/news/304452376.md)
- [AI solves 167-year-old maths problem, Anthropic researcher claims](https://longbridge.com/en/news/306318851.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**